RxDoctor Payments Data

Casey Cosgrove, MD

Gynecologic Oncology · Hilliard, OHNPI 1124387006

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $24,930 of the $29,968 with a category attached, or 83.2%. 9 manufacturers reported payments, led by GSK at 45.3% of the total. Among gynecologic oncology clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$29,968in general payments, 2019–2025

Across 39 payments — averaging $768.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$14K
  • AstraZeneca$6K
  • AbbVie$4K
  • Merck$4K
  • Intuitive Surgical$3K
  • Karyopharm Therapeutics Inc.$193
  • plus $240 from 3 others
$4,029,493in research payments, 2019–2025

Across 59 payments — averaging $68,296 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GSK$3.6M
  • Regeneron$250K
  • Merck$135K
  • Genmab A/s$33K
  • Seagen Inc.$8K

What the payments were for

  • Consulting fees$24,93083%
  • Speaking & faculty fees$1,0003%
  • Travel & lodging$1,9046%
  • Food & beverage$1,1344%
  • Education$1,0003%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,968 in reported general payments places this provider in the 90th percentile of 62 gynecologic oncology providers in Ohio.

See all gynecologic oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$109,954
Medicare patients
185
Services billed
1,320

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LynparzaOlaparib23$318,217

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLynparza$5,587$318,21723 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 62 gynecologic oncology providers in Ohio.

Other gynecologic oncology in Hilliard

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →